8-K: Ionis Pharmaceuticals Licenses Sapablursen to Ono Pharmaceutical in $940 Million Deal

Ionis Pharmaceuticals grants Ono Pharmaceutical exclusive global rights to develop and commercialize sapablursen for polycythemia vera in a deal worth up to $940 million.

Summary

• Ionis Pharmaceuticals has entered into a license agreement with Ono Pharmaceutical for sapablursen, an investigational RNA-targeted medicine for polycythemia vera (PV).
• Ono Pharmaceutical obtains exclusive global rights for the development and commercialization of sapablursen.
• Ionis will receive a $280 million upfront payment.
• Ionis is eligible to receive up to $660 million in additional payments based on development, regulatory, and sales milestones.
• Ionis is also eligible to earn royalties in the mid-teen percentage range on annual net sales of sapablursen.
• Ionis will complete the ongoing Phase 2 IMPRSSION study.
• Ono will be responsible for subsequent development, regulatory filings, and commercialization.
• Sapablursen has received Fast Track designation and orphan drug designation from the FDA in 2024.

Sentiment

Score: 8

Explanation: The announcement is positive due to the significant upfront payment, potential milestone payments, and royalties for Ionis. It also allows Ionis to focus on its core pipeline. Ono also benefits from acquiring a promising drug candidate.

Positives

• Ionis receives a significant upfront payment of $280 million.
• The deal provides potential for up to $660 million in milestone payments.
• Ionis will receive royalties on future sales of sapablursen.
• The agreement allows Ionis to focus on its wholly-owned medicines and commercial opportunities.
• Ono's expertise will help maximize the value of sapablursen and ensure broad access for patients.

Risks

• The transaction is subject to the requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act).
• Forward-looking statements are subject to risks and uncertainties related to commercial products, medicines in the pipeline, and the process of discovering, developing, and commercializing medicines.

Future Outlook

Ionis anticipates three additional launches in the next three years and expects streamlining its portfolio to provide financial flexibility and support revenue growth.

Management Comments

• Brett P. Monia, Ph.D., chief executive officer, Ionis, stated, 'We are pleased to entrust sapablursen to Ono, whose unique capabilities will help maximize its value by ensuring broad access for people living with PV.'
• Toichi Takino, president and COO, Ono, stated, 'We are delighted to enter into this collaboration with Ionis Pharmaceuticals, a pioneer in RNA-targeted medicines, for sapablursen. This partnership aligns with our strategy to strengthen our pipeline in hematology. We expect sapablursen to become a new treatment option for PV patients worldwide.'

Industry Context

This agreement reflects a trend in the pharmaceutical industry where companies specialize and partner to advance drug development and commercialization, particularly for rare diseases. Ono's focus on hematology aligns with the potential of sapablursen in treating polycythemia vera.

Comparison to Industry Standards

• Licensing deals in the pharmaceutical industry vary widely, but upfront payments and potential milestone payments in this range are common for drugs in Phase 2 development, especially for rare diseases.
• Comparable deals include [hypothetical example] where Company X licensed a Phase 2 asset for a similar indication for $250 million upfront and up to $600 million in milestones.
• The mid-teen royalty rate is within the typical range for pharmaceutical licensing agreements, which can range from single digits to the low twenties depending on the stage of development and market potential.

Stakeholder Impact

• Shareholders of Ionis will benefit from the upfront payment and potential future revenue.
• Patients with polycythemia vera may benefit from a new treatment option.
• Ono Pharmaceutical strengthens its pipeline in hematology.

Next Steps

• Ionis will complete the ongoing Phase 2 IMPRSSION study.
• Ono will be responsible for subsequent development, regulatory filings, and commercialization.
• The transaction is subject to the requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act).

Key Dates

Keywords

sapablursen, polycythemia vera, Ono Pharmaceutical, Ionis Pharmaceuticals, license agreement, RNA-targeted medicine, hematologic disease, FDA, Fast Track designation, orphan drug designation, milestone payments, royalties